UACC-1598細(xì)胞

生長狀態(tài)： 貼壁生長

年限： 78 years

細(xì)胞形態(tài)： 上皮樣

數(shù)量： 大量

運(yùn)輸方式： 凍存運(yùn)輸

ATCC Number： CRL-3128?

相關(guān)**： 其他**

是否是腫瘤細(xì)胞： 0

物種來源： 人

器官來源： 卵巢

UACC-1598細(xì)胞Designations: UACC-1598

Depositors: K Brown

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial-like

Source: Organ: ovary

Disease: cystadenocarcinoma

Tumor Stage: Grade IV

Cellular Products: cytokeratin (MAK-6), not expressed

progesterone, not expressed

Permits/Forms: UACC-1598細(xì)胞In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Isolation: Isolation date: January 1989

Applications: Pathology confirmed that the specimen was a grade IV poorly differentiated papillary serous cystadenocarcinoma.

The human ovarian cancer cell line, UACC-1598, was derived from the right ovary of an untreated 78-year-old female.

The UACC-1598 cell line expresses the N-myc oncogene, which is rarely amplified in ovarian cancers.

UACC-1598 cells express low levels of Epidermal Growth Factor Receptor erbB2, and are negative for ras by ELISA assay.

A high copy number amplification of eukaryotic translation initiation factor 5A2 (eIF-5A2) oncogene was detected in this region.

Receptors: Epidermal Growth Factor Receptor (EGFR), low expression

Oncogene: N-myc, positive; eukaryotic translation initiation factor 5A2 (eIF-5A2), positive; c-erbB2, low expression; ras, negative

DNA Profile (STR): CSF1PO: 10

D13S317: 13

D16S539: 11, 12

D5S818: 13

D7S820: 7, 9

THO1: 7, 9.3

UACC-1598細(xì)胞TPOX: 8, 11

vWA: 14

Amelogenin: X

Age: 78 years

Gender: female

Comments: The human ovarian cancer cell line, UACC-1598, was derived from the right ovary of an untreated 78-year-old female. Pathology confirmed that the specimen was a grade IV poorly differentiated papillary serous cystadenocarcinoma.

The UACC-1598 cell line expresses the N-myc oncogene, which is rarely amplified in ovarian cancers.

UACC-1598 cells express low levels of Epidermal Growth Factor Receptor erbB2, and are negative for ras by ELISA assay.

The UACC-1598 cell line contains high-level amplification at 3q26 in the form of double minute chromosomes. A high copy number amplification of eukaryotic translation initiation factor 5A2 (eIF-5A2) oncogene was detected in this region. Overexpression the eIF-5A2 oncogene may play an important role in ovarian cancer pathogenesis. [16173601]

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium:

fetal bovine serum to a final concentration of 5%

0.01 mg/ml transferrin (final conc.)

0.01 mg/ml insulin (final conc.)

5 &microg/mLUACC-1598細(xì)胞 (55 U/ml) catalase (final conc.)

3.6 &microg/mL (0.01 mM) hydrocortisone (final conc.)

70 &microg/mL (0.5mM) o-phosphoethanolamine (final conc.)

10 ng/ml human recombinant epidermal growth factor (EGF) (final conc.)

3 ng/ml (0.01 ?M) estradiol (final conc.)

0.8 ng/ml (1 pM) Na-L-thyroxine (final conc.)

extra 2 mM glutamine

Note: Do not filter complete medium.

Temperature: 37.0°C

Atmosphere: air, 100%

Growth Conditions: These cells grow very slowly.

Subculturing: Protocol:

UACC-1598細(xì)胞Subculture when cells reach 80% to 90% confluence. These cells pile up and slough off the flask surface if they become over-confluent.

Volumes used in this protocol are for 75 cm2 flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.

Remove and discard culture medium.

Briefly rinse the cell layer with Ca++/Mg++ free Dulbecco's phosphate-buffered saline (D-PBS) or 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.

Add 1.0 to 2.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).

Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37.0°C to facilitate dispersal.

Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.

Transfer cell suspension to a centrifuge tube and spin at approximately 125 x g for 5 to 10 minutes. Discard supernatant.

Resuspend the cell pellet in fresh growth medium. Add appropriate aliquots of the cell suspension to new culture vessels.

Incubate cultures at 37.0°C in atmospheric air without additional CO2.

Subcultivation ratio: A subcultivation ratio of 1:2 is recommended.

Medium renewal: every 5 to 7 days

Preservation: Freeze medium: complete growth medium supplemented with an additional 10% fetal bovine serum (FBS) and 10% (v/v) DMSO

Storage temperature: liquid nitrogen vapor phase

Related Products: Recommended medium (without the additional serum described under ATCC Medium): ATCC 30-2008

Recommended serum: ATCC 30-2020

Cell culture tested DMSO: ATCC 4-X

0.25% (w/v) Trypsin - 0.53mM EDTA in Hank's BSS (w/o Ca++, Mg ++): ATCC 30-2101

Phosphate-buffered saline: ATCC 30-2200

L-Glutamine solution, 200mM: ATCC 30-2214

Erythrosin B vital stain solution: ATCC 30-2404

References: 16173530: Heiskanen MA, et al. Detection of gene amplification by genomic hybridization to cDNA microarrays. Cancer Res. 60(4): 799-802, 2000. PubMed: 10706083

16173531: Guan XY, et al. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res. 61(9): 3806-3809, 2001. PubMed: 11325856

16173601: Guan XY, et al. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Research 64 (12): 4197-4200, 2004. PubMed: 15205331

16174065: Clement P, et al. Identification and characterization of eukaryotic initiation factor 5A-2. Eur. J. Biochem. 147(21): 4254-4263, 2003. PubMed: 14622290

16174066: Clement P, et al. Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J. 273(6): 1102-1114: 2006. PubMed: 16519677